CentraState Healthcare System Partners with Noteworth to Deliver Telemedicine Services and Extend Care Management Capabilities
Virtual care platform successfully expands access to care and improves internal workflows
News provided by
Share this article
HOBOKEN, N.J., Feb. 3, 2021 /PRNewswire/
Noteworth, a first-of-its-kind virtual care delivery platform, today announced its partnership with CentraState Healthcare System to extend the continuity of care for patients in the community. CentraState recently implemented Noteworth to launch multiple programs to expand their care delivery, including telehealth and remote prevention and care management capabilities for diabetes and hypertension. Having worked with various vendors for over 20 years, Noteworth is at the top of my list. Not only are their products aiding our patients, the process improvements have allowed our staff to see more patients in the same number of hours, Brian Dusheck, Director, Ambulatory Applications at
E-Mail
Rutgers researchers have been awarded $1.6 million from the National Institutes of Health in support of the creation of a national collaborative network seeking to identify risk and protective factors that may allow clinicians or public health professionals to predict which children are at greatest risk for serious illness from SARS-CoV-2 infection, the virus that causes COVID-19.
While children are less likely than adults to become severely ill, some develop severe acute respiratory illness; they also are susceptible to multisystem inflammatory syndrome of children (MIS-C), a critical illness that can occur several weeks after infection.
The two-year grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the NIH will support the development of a national network of networks, thus building an infrastructure that ensures that children from around the country can be a part of the study. The project is designed to incorpor
Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment
Research by Rutgers Cancer Institute of New Jersey and RWJBarnabas Health researcher and international collaborators can help identify prognosis and stratify risk
News provided by
Share this article
(PRNewsfoto/Rutgers Cancer Institute of New Jersey and RWJBarnabas Health)
NEW BRUNSWICK, N.J., Jan. 28, 2021 /PRNewswire/ Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and a National Cancer Institute- designated Comprehensive Cancer Center, together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. The research from the Burkitt Lymphoma International Prognostic Index Consortium is published in the January 2021 online issue of
Press Releases
Senate President Sweeney, Honorable Members of the NJ Legislative Disability Caucus & Advocates from the Disability Community Hold First Meeting of Bipartisan Disability Caucus Focusing on the Impact of COVID-19 on Persons with Disabilities January 27, 2021, 1:15 pm | in
Senate President Sweeney, Honorable Members of the NJ Legislative Disability Caucus & Advocates from the Disability Community Hold First Meeting of Bipartisan Disability Caucus Focusing on the Impact of COVID-19 on Persons with Disabilities
TRENTON, NJ New Jersey Legislative Disability Caucus Chair Senate President Steve Sweeney, honorable legislative caucus members and advocates from the disability community met virtually on January 26th for the inaugural meeting of the Caucus to discuss the impact of COVID-19 on people with disabilities. With the COVID-19 pandemic taking a disproportionate toll on people with disabilities, the topic led to a robust discussion among
The rollout of the COVID-19 vaccine has sparked hope that schools will be able to return to normal following a pandemic that has upended traditional learning.
But many questions remain about how and when vaccines will be given and when schools can resume daily, in-person operations. Teachers have yet to get the shots, while a children’s version of the inoculation still is in the clinical trial phase.
The success of the vaccination program also depends on whether enough people participate at a time when many Americans still express skepticism and mistrust in the newly developed medicines. Lawmakers could require it for students, but a loophole for religious exemptions remains on the books.